{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:08:31Z","timestamp":1787170111538,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Research Project on the Integration of Traditional Chinese and Western Medicine Conducted at Southwest Medical University","award":["2024ZXYZX06"],"award-info":[{"award-number":["2024ZXYZX06"]}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["25ZDIZX027"],"award-info":[{"award-number":["25ZDIZX027"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Science and Technology Program","award":["2025NSFSC2163"],"award-info":[{"award-number":["2025NSFSC2163"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07362-w","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:44:41Z","timestamp":1763034281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial\u2013mesenchymal transition in chronic hepatic injury"],"prefix":"10.1186","volume":"23","author":[{"given":"Bingwen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"7362_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7362_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425\u201356.","journal-title":"Annu Rev Pathol"},{"key":"7362_CR3","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola M, Pinzani M. Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med. 2024;95:101231.","journal-title":"Mol Aspects Med"},{"key":"7362_CR4","doi-asserted-by":"publisher","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Friedman SL. Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med. 2023;15:eadi0759.","journal-title":"Sci Transl Med"},{"key":"7362_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","volume":"81","author":"V Taru","year":"2024","unstructured":"Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81:895\u2013910.","journal-title":"J Hepatol"},{"key":"7362_CR6","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29:S17\u201331.","journal-title":"Clin Mol Hepatol"},{"key":"7362_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2024.10.015","volume":"82","author":"Q Huang","year":"2025","unstructured":"Huang Q, Qadri SF, Bian H, Yi X, Lin C, Yang X, Zhu X, Lin H, Yan H, Chang X, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease. J Hepatol. 2025;82:781\u201393.","journal-title":"J Hepatol"},{"key":"7362_CR8","doi-asserted-by":"crossref","unstructured":"Ma C, Wang S, Dong B, Tian Y. Metabolic reprograming of immune cells in MASH. Hepatology; 2025.","DOI":"10.1097\/HEP.0000000000001371"},{"key":"7362_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12967-025-06490-7","volume":"23","author":"W Zhang","year":"2025","unstructured":"Zhang W, Lu W, Jiao Y, Li T, Wang H, Wan C. Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learning. J Transl Med. 2025;23:472.","journal-title":"J Transl Med"},{"key":"7362_CR10","doi-asserted-by":"publisher","first-page":"156472","DOI":"10.1016\/j.phymed.2025.156472","volume":"139","author":"X Yin","year":"2025","unstructured":"Yin X, Liu Z, Li C, Wang J. Hinokitiol ameliorates MASH in mice by therapeutic targeting of hepatic Nrf2 and inhibiting hepatocyte ferroptosis. Phytomedicine. 2025;139:156472.","journal-title":"Phytomedicine"},{"key":"7362_CR11","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1021\/acs.jmedchem.4c02658","volume":"68","author":"T Bi","year":"2025","unstructured":"Bi T, Liang P, Zhao Q, Wu J, Zhou Y, Xu Y, Fan X, Yang G, Sun Q, Ren W, et al. Targeted degradation of Bromodomain-Containing protein 4 enabled by reactive oxygen Species-Activatable nanoprotacs as an efficient strategy to reverse liver fibrosis in chronic liver injury. J Med Chem. 2025;68:6328\u201338.","journal-title":"J Med Chem"},{"key":"7362_CR12","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology 2024.","DOI":"10.1097\/HEP.0000000000000786"},{"key":"7362_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther. 2022;7:206.","journal-title":"Signal Transduct Target Ther"},{"key":"7362_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68:238\u201350.","journal-title":"J Hepatol"},{"key":"7362_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcmgh.2023.09.008","volume":"17","author":"HY Kim","year":"2024","unstructured":"Kim HY, Sakane S, Eguileor A, Carvalho Gontijo Weber R, Lee W, Liu X, Lam K, Ishizuka K, Rosenthal SB, Diggle K, et al. The origin and fate of liver myofibroblasts. Cell Mol Gastroenterol Hepatol. 2024;17:93\u2013106.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"7362_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/hep.28948","volume":"65","author":"T Kisseleva","year":"2017","unstructured":"Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic liver. Hepatology. 2017;65:1039\u201343.","journal-title":"Hepatology"},{"key":"7362_CR17","doi-asserted-by":"publisher","first-page":"156823","DOI":"10.1016\/j.phymed.2025.156823","volume":"143","author":"X Zhao","year":"2025","unstructured":"Zhao X, Xia F, Dong Z, Huang W, Kong X, Cui Z, Yan M, Gao H, Rong R, Wang M, et al. A novel EndMT inhibitor, xanthotoxin, attenuates non-alcoholic fatty liver disease by acting as TGFbetaR2 antagonist. Phytomedicine. 2025;143:156823.","journal-title":"Phytomedicine"},{"key":"7362_CR18","doi-asserted-by":"publisher","first-page":"156307","DOI":"10.1016\/j.phymed.2024.156307","volume":"136","author":"Y Gao","year":"2025","unstructured":"Gao Y, Ye F, Dong Y, Wang T, Xiong L, Chen T, Wang Y, Liu X, Zhang Y, Qiu Z, et al. Salvianic acid A ameliorates atherosclerosis through metabolic-dependent anti-EndMT pathway and repression of TGF-beta\/ALK5 signaling. Phytomedicine. 2025;136:156307.","journal-title":"Phytomedicine"},{"key":"7362_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-022-03352-4","volume":"20","author":"X Li","year":"2022","unstructured":"Li X, Lu L, Hou W, Wang F, Huang T, Meng Z, Zhu M. The SETD8\/ELK1\/bach1 complex regulates hyperglycaemia-mediated EndMT in diabetic nephropathy. J Transl Med. 2022;20:147.","journal-title":"J Transl Med"},{"key":"7362_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952\u201361.","journal-title":"Nat Med"},{"key":"7362_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12967-025-06505-3","volume":"23","author":"Q Jiao","year":"2025","unstructured":"Jiao Q, Xu X, Xu L, Wang Y, Pang S, Hao J, Liu X, Zhao Y, Qi W, Qin L, et al. Knockdown of eIF3a alleviates pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition via TGFbeta1\/SMAD pathway. J Transl Med. 2025;23:524.","journal-title":"J Transl Med"},{"key":"7362_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1186\/s12967-024-05546-4","volume":"22","author":"L Zhang","year":"2024","unstructured":"Zhang L, Ge T, Cui J. FLI-1-driven regulation of endothelial cells in human diseases. J Transl Med. 2024;22:740.","journal-title":"J Transl Med"},{"key":"7362_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcdb.2019.10.015","volume":"101","author":"X Sun","year":"2020","unstructured":"Sun X, Nkennor B, Mastikhina O, Soon K, Nunes SS. Endothelium-mediated contributions to fibrosis. Semin Cell Dev Biol. 2020;101:78\u201386.","journal-title":"Semin Cell Dev Biol"},{"key":"7362_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12967-024-05399-x","volume":"22","author":"TT Liu","year":"2024","unstructured":"Liu TT, Sun HF, Tang MZ, Shen HR, Shen Z, Han YX, Zhan Y, Jiang JD. Bicyclol attenuates pulmonary fibrosis with silicosis via both canonical and non-canonical TGF-beta1 signaling pathways. J Transl Med. 2024;22:682.","journal-title":"J Transl Med"},{"key":"7362_CR25","doi-asserted-by":"publisher","first-page":"111355","DOI":"10.1016\/j.cellsig.2024.111355","volume":"123","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Liang P, Bi T, Tang B, Zhu X, Liu X, Wang H, Shen H, Sun Q, Yang S, Ren W. Angiotensin II depends on hippo\/YAP signaling to reprogram angiogenesis and promote liver fibrosis. Cell Signal. 2024;123:111355.","journal-title":"Cell Signal"},{"key":"7362_CR26","doi-asserted-by":"publisher","first-page":"153461","DOI":"10.1016\/j.phymed.2021.153461","volume":"82","author":"J Gu","year":"2021","unstructured":"Gu J, Qiu M, Lu Y, Ji Y, Qian Z, Sun W. Piperlongumine attenuates angiotensin-II-induced cardiac hypertrophy and fibrosis by inhibiting Akt-FoxO1 signalling. Phytomedicine. 2021;82:153461.","journal-title":"Phytomedicine"},{"key":"7362_CR27","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/HYPERTENSIONAHA.122.18657","volume":"79","author":"Z Xu","year":"2022","unstructured":"Xu Z, Luo W, Chen L, Zhuang Z, Yang D, Qian J, Khan ZA, Guan X, Wang Y, Li X, Liang G, Ang II. (Angiotensin II)-Induced FGFR1 (Fibroblast growth factor receptor 1) activation in tubular epithelial cells promotes hypertensive kidney fibrosis and injury. Hypertension. 2022;79:2028\u201341.","journal-title":"Hypertension"},{"key":"7362_CR28","doi-asserted-by":"publisher","first-page":"e2300706120","DOI":"10.1073\/pnas.2300706120","volume":"120","author":"L Gu","year":"2023","unstructured":"Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, et al. Angiotensin II receptor Inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023;120:e2300706120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7362_CR29","doi-asserted-by":"publisher","first-page":"110935","DOI":"10.1016\/j.cellsig.2023.110935","volume":"113","author":"Y An","year":"2024","unstructured":"An Y, Xu C, Liu W, Jiang J, Ye P, Yang M, Zhu W, Yu J, Yu M, Sun W, et al. Angiotensin II type-2 receptor attenuates liver fibrosis progression by suppressing IRE1alpha-XBP1 pathway. Cell Signal. 2024;113:110935.","journal-title":"Cell Signal"},{"key":"7362_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/hep.27117","volume":"60","author":"M Granzow","year":"2014","unstructured":"Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, Mazar IG, Gortzen J, Vogt A, Schildberg FA, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology. 2014;60:334\u201348.","journal-title":"Hepatology"},{"key":"7362_CR31","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"SJ Forrester","year":"2018","unstructured":"Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98:1627\u2013738.","journal-title":"Physiol Rev"},{"key":"7362_CR32","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/cvr\/cvad086","volume":"119","author":"X Wei","year":"2023","unstructured":"Wei X, Jin J, Wu J, He Y, Guo J, Yang Z, Chen L, Hu K, Li L, Jia M, et al. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+\/CaMKII pathway. Cardiovasc Res. 2023;119:1842\u201355.","journal-title":"Cardiovasc Res"},{"key":"7362_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1136\/annrheumdis-2021-222088","volume":"81","author":"X Yue","year":"2022","unstructured":"Yue X, Yin J, Wang X, Heidecke H, Hackel AM, Dong X, Kasper B, Wen L, Zhang L, Schulze-Forster K, et al. Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching. Ann Rheum Dis. 2022;81:1281\u20139.","journal-title":"Ann Rheum Dis"},{"key":"7362_CR34","doi-asserted-by":"crossref","unstructured":"Kuang X, Naiki-Ito A, Kawamura H, Murakami A, Komura M, Kato H, et al. Hepatic stellate cell Inhibition by angiotensin II receptor blocker mitigates liver injury and fibrosis via NF-kappaB-galectin-3 suppression in a rat nonalcoholic steatohepatitis model. Arch Toxicol. 2025;99(8):3393\u2013412.","DOI":"10.1007\/s00204-025-04075-3"},{"key":"7362_CR35","doi-asserted-by":"crossref","unstructured":"Slomski A. Losartan decreases incidence of epilepsy in arterial hypertension. JAMA 2022, 328:2099.","DOI":"10.1001\/jama.2022.20025"},{"key":"7362_CR36","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, Dungen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42:3741\u201352.","journal-title":"Eur Heart J"},{"key":"7362_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Effects of Sacubitril\/Valsartan versus Olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69:411\u201320.","journal-title":"Hypertension"},{"key":"7362_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.17235\/reed.2016.4340\/2016","volume":"108","author":"E Saez Gonzalez","year":"2016","unstructured":"Saez Gonzalez E, Diaz Jaime FC, Del Val Antonana A. Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with Olmesartan use. Rev Esp Enferm Dig. 2016;108:685\u20136.","journal-title":"Rev Esp Enferm Dig"},{"key":"7362_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/1028415X.2023.2180865","volume":"27","author":"M Farzan","year":"2024","unstructured":"Farzan M, Farzan M, Shahrani M, Navabi SP, Vardanjani HR, Amini-Khoei H, Shabani S. Neuroprotective properties of Betulin, betulinic acid, and ursolic acid as triterpenoids derivatives: a comprehensive review of mechanistic studies. Nutr Neurosci. 2024;27:223\u201340.","journal-title":"Nutr Neurosci"},{"key":"7362_CR40","doi-asserted-by":"publisher","first-page":"116295","DOI":"10.1016\/j.jep.2023.116295","volume":"309","author":"L Tao","year":"2023","unstructured":"Tao L, Zhou K, Zhao Y, Xia X, Guo Y, Gao Y, Peng G, Liu Y. Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation. J Ethnopharmacol. 2023;309:116295.","journal-title":"J Ethnopharmacol"},{"key":"7362_CR41","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.3892\/mmr.2016.5792","volume":"14","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hu J, Chen Y. Betulinic acid and the Pharmacological effects of tumor suppression (Review). Mol Med Rep. 2016;14:4489\u201395.","journal-title":"Mol Med Rep"},{"key":"7362_CR42","doi-asserted-by":"publisher","first-page":"105617","DOI":"10.1016\/j.fitote.2023.105617","volume":"169","author":"H Mu","year":"2023","unstructured":"Mu H, Sun Y, Yuan B, Wang Y. Betulinic acid in the treatment of breast cancer: application and mechanism progress. Fitoterapia. 2023;169:105617.","journal-title":"Fitoterapia"},{"key":"7362_CR43","doi-asserted-by":"publisher","first-page":"e23206","DOI":"10.1002\/jbt.23206","volume":"36","author":"M Aswathy","year":"2022","unstructured":"Aswathy M, Vijayan A, Daimary UD, Girisa S, Radhakrishnan KV, Kunnumakkara AB. Betulinic acid: A natural promising anticancer drug, current situation, and future perspectives. J Biochem Mol Toxicol. 2022;36:e23206.","journal-title":"J Biochem Mol Toxicol"},{"key":"7362_CR44","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.2147\/IJN.S373430","volume":"17","author":"ZC Wu","year":"2022","unstructured":"Wu ZC, Liu XY, Liu JY, Piao JS, Piao MG. Preparation of betulinic acid galactosylated Chitosan nanoparticles and their effect on liver fibrosis. Int J Nanomed. 2022;17:4195\u2013210.","journal-title":"Int J Nanomed"},{"key":"7362_CR45","doi-asserted-by":"publisher","first-page":"115459","DOI":"10.1016\/j.jep.2022.115459","volume":"296","author":"H Zhao","year":"2022","unstructured":"Zhao H, Wu L, Zhang Y, Feng S, Ding Y, Deng X, Feng R, Li J, Ma T, Huang C. Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation. J Ethnopharmacol. 2022;296:115459.","journal-title":"J Ethnopharmacol"},{"key":"7362_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cbi.2012.01.002","volume":"195","author":"Y Wan","year":"2012","unstructured":"Wan Y, Wu YL, Lian LH, Xie WX, Li X, Ouyang BQ, Bai T, Li Q, Yang N, Nan JX. The anti-fibrotic effect of betulinic acid is mediated through the Inhibition of NF-kappaB nuclear protein translocation. Chem Biol Interact. 2012;195:215\u201323.","journal-title":"Chem Biol Interact"},{"key":"7362_CR47","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3:100316.","journal-title":"JHEP Rep"},{"key":"7362_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24:171\u201389.","journal-title":"Nat Rev Drug Discov"},{"key":"7362_CR49","doi-asserted-by":"publisher","first-page":"112059","DOI":"10.1016\/j.celrep.2023.112059","volume":"42","author":"C Ortiz","year":"2023","unstructured":"Ortiz C, Klein S, Reul WH, Magdaleno F, Groschl S, Dietrich P, Schierwagen R, Uschner FE, Torres S, Hieber C, et al. Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1. Cell Rep. 2023;42:112059.","journal-title":"Cell Rep"},{"key":"7362_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cmet.2020.11.019","volume":"33","author":"Y Chen","year":"2021","unstructured":"Chen Y, Pu Q, Ma Y, Zhang H, Ye T, Zhao C, Huang X, Ren Y, Qiao L, Liu HM, et al. Aging reprograms the Hematopoietic-Vascular niche to impede regeneration and promote fibrosis. Cell Metab. 2021;33:395\u2013e410394.","journal-title":"Cell Metab"},{"key":"7362_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lfs.2018.07.056","volume":"209","author":"P Kumar","year":"2018","unstructured":"Kumar P, Bhadauria AS, Singh AK, Saha S. Betulinic acid as apoptosis activator: molecular mechanisms, mathematical modeling and chemical modifications. Life Sci. 2018;209:24\u201333.","journal-title":"Life Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07362-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:02:46Z","timestamp":1763035366000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7362"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07362-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol involving mice was formally approved by the Animal Care and Use Committee of Southwest Medical University to ensure strict adherence to the highest ethical principles and regulatory guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript and gave their consent for submission and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1282"}}